

b.) Amendment to the Claims:

1. (Currently Amended) A medicament comprising a combination of a recombinant antibody which specifically binds to human CC chemokine receptor 4 (CCR4) or an antibody fragment thereof and at least one pharmaceutically active agent, together with a pharmaceutically acceptable carrier.

Claim 2 (Cancelled).

3. (Currently Amended) ~~A medicament for administering kit,~~
comprising a recombinant antibody which specifically binds to CCR4 or an antibody fragment ~~thereof~~ thereof, and at least one pharmaceutically active agent ~~either simultaneously or successively~~.

4. (Currently Amended) The medicament according to ~~any one of the~~
~~claims 1 to 3, which~~ claim 1, wherein the pharmaceutically active agent is an antitumor drug.

5. (Currently Amended) ~~The medicament according to the claim 4,~~
~~wherein the tumor is a~~ A process of treating tumor in which CCR4 is expressed comprising

administering the medicament according to any one of claims 4 or 7-20 to a patient in need thereof.

6. (Currently Amended) The ~~medicament~~ process according to the claim 5, wherein the tumor ~~in which CCR4 is expressed~~ is a hematopoietic organ tumor.

7. (Currently Amended) The medicament according to ~~any one of the claims 1 to 6~~ claim 4, wherein the recombinant antibody which specifically binds to CCR4 or the antibody fragment thereof is an antibody which specifically binds to an extracellular region of CCR4 and does not show a reactivity to a human platelet.

8. (Currently Amended) The medicament according to the claim 7, wherein the recombinant antibody which specifically binds to the extracellular region of CCR4 or the antibody fragment thereof does not have an activity of inhibiting binding of TARC (~~thymus and activation regulated chemokine~~) or MDC (~~macrophage derived chemokine~~) as a CCR4 ligand to CCR4.

9. (Currently Amended) The medicament according to ~~the claim 7 or 8~~ claim 8, wherein the extracellular region is an extracellular region selected from the group

consisting of 1 to 39, 98 to 112, 176 to 206 and 271 to 284 of an amino acid sequence represented by SEQ ID No. 1.

10. (Currently Amended) The medicament according to ~~any one of the claims 7 to 9~~ claim 8, wherein the extracellular region is an epitope existing at positions 2 to 29 of the amino acid sequence represented by SEQ ID No. 1.

11. (Currently Amended) The medicament according to ~~any one of the claims 7 to 10~~ claim 8, wherein the extracellular region is an epitope existing at positions 13 to 29 of the amino acid sequence represented by SEQ ID No. 1.

12. (Currently Amended) The medicament according to ~~any one of the claims 7 to 11~~ claim 8, wherein the extracellular region is an epitope existing at positions 13 to 25 of the amino acid sequence represented by SEQ ID No. 1.

13. (Original) The medicament according to the claim 12, wherein in the recombinant antibody which specifically binds to CCR4 or the antibody fragment thereof, a binding activity to a peptide comprising 13 to 25 of the amino acid sequence represented by SEQ ID No. 1 in which at least one of tyrosine residues 16, 19, 20 and 22 is

sulfated is lower than a binding activity to a peptide comprising 13 to 25 of the amino acid sequence represented by SEQ ID No. 1.

14. (Currently Amended) The medicament according to ~~any one of the claims 1 to 13~~ claim 13, wherein the recombinant antibody which specifically binds to the extracellular region of CCR4 or the antibody fragment thereof is an antibody which specifically reacts with an epitope recognized by a monoclonal antibody which hybridoma KM 2160 (FERM BP-10090) produces or an antibody fragment thereof.

15. (Currently Amended) The medicament according to ~~any one of the claims 1 to 14~~ claim 13, wherein the human recombinant antibody is a human chimeric antibody or a human CDR-grafted antibody.

16. (Original) The medicament according to the claim 15, wherein the human chimeric antibody comprises complementarity determining regions (CDRs) of a heavy chain (H chain) variable region (V region) and a light chain (L chain) V region of a monoclonal antibody which specifically binds to CCR4.

17. (Currently Amended) The medicament according to ~~the claim 15 or 16~~ claim 16, wherein the human chimeric antibody comprises CDR1, CDR2 and CDR3 of

a heavy chain (H chain) variable region (V region) of an antibody comprising amino acid sequences represented by SEQ ID Nos. 5, 6 and 7, respectively and/or CDR1, CDR2 and CDR3 of a light chain (L chain) variable region (V region) of an antibody comprising amino acid sequences represented by SEQ ID Nos. 8, 9 and 10, respectively.

18. (Currently Amended) The medicament according to ~~the claims 15 to 17~~ claim 17, wherein the human chimeric antibody comprises a heavy chain (H chain) variable region (V region) of an antibody molecule comprising an amino acid sequence represented by SEQ ID No. 11 and/or a light chain (L chain) V region of an antibody molecule represented by SEQ ID No. 12.

19. (Original) The medicament according to the claim 15, wherein the human CDR-grafted antibody comprises complementarity determining regions (CDRs) of a heavy chain (H chain) variable region (V region) and a light chain (L chain) V region of a monoclonal antibody which specifically binds to CCR4.

20. (Currently Amended) The medicament according to ~~the claim 15 or 19~~ claim 19, wherein the human CDR-grafted antibody comprises CDR1, CDR2 and CDR3 of a heavy chain (H chain) variable region (V region) of an antibody comprising amino acid sequences represented by SEQ. ID Nos. 5, 6 and 7, respectively and/or CDR1,

CDR2 and CDR3 of a light chain (L chain) V region comprising amino acid sequences represented by SEQ ID Nos. 8, 9 and 10, respectively.

21. (Original) The medicament according to any one of the claims 15, 18 and 20, wherein the human CDR-grafted antibody comprises a heavy chain (H chain) variable region (V region) of an antibody molecule comprising an amino acid sequence represented by SEQ ID No. 16 or 17 and/or a light chain (L chain) V region of an antibody molecule represented by SEQ ID No. 18.

22. (Currently Amended) The medicament according to ~~any one of the claims 1 to 21~~ claim 21, wherein the agent is a protein or an agent having low-molecular weight.

23. (Original) The medicament according to the claim 22, wherein the protein is a cytokine or an antibody.

24. (Original) The medicament according to the claim 23, wherein the cytokine is a cytokine selected from G-CSF, M-CSF, interferon- α , IL-2 and IL-15.

25. (Currently Amended) The medicament according to ~~any one of the~~
~~claims 1 to 24~~ claim 24, wherein the agent having low-molecular weight is a
chemotherapeutic agent or a hormone therapeutic agent.

26. (Original) The medicament according to the claim 25, wherein the
chemotherapeutic agent is an agent selected from vincristine, cyclophosphamide, etoposide
and Methotrexate.